Sun-Novo(SH:688621) Xin Lang Cai Jing·2025-12-19 02:10Group 1 - The core point of the news is that Yangguang Nuohuo's stock price increased by 5.08% to 67.80 CNY per share, with a total market capitalization of 7.594 billion CNY as of the report date [1] - Yangguang Nuohuo is primarily engaged in the development of generic drugs, consistency evaluation, and innovative drug development, with 99.91% of its revenue coming from CRO services [1] - The company is located in Changping District, Beijing, and was established on March 9, 2009, with its listing date on June 21, 2021 [1] Group 2 - The top circulating shareholder of Yangguang Nuohuo is a fund under Rongtong Fund, which reduced its holdings by 550,000 shares in the third quarter, now holding 2 million shares, accounting for 1.79% of circulating shares [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund has a total scale of 1.816 billion CNY and has achieved a return of 10.14% this year [2] - The fund manager, Wan Minyuan, has a tenure of 9 years and 118 days, with the best fund return during this period being 130.26% [3] Group 3 - The Rongtong Health Industry Flexible Allocation Mixed A/B fund has Yangguang Nuohuo as its sixth-largest heavy stock, with 5.44% of the fund's net value [4] - The fund's floating profit from its holdings in Yangguang Nuohuo is approximately 6.56 million CNY [4]